Related Experiment Videos
Neurologic sequelae of methotrexate and ionizing radiation: a new classification
Cancer Treatment Reports
|January 1, 1981
Summary
Central nervous system (CNS) leukemia prevention improves survival in acute lymphoblastic leukemia (ALL) patients. However, some survivors experience neurotoxicity, with combined CNS irradiation and methotrexate being most toxic, while high-dose iv methotrexate appears safest.
Area of Science:
- Pediatric Oncology
- Neuro-oncology
- Hematology
Background:
- Central nervous system (CNS) leukemia prophylaxis significantly improves disease-free survival in pediatric acute lymphoblastic leukemia (ALL) patients.
- Long-term survivors of ALL treated with CNS prophylaxis may experience residual neurologic dysfunction, ranging from intellectual deficits to leukoencephalopathy.
Purpose of the Study:
- To categorize neurotoxicities associated with methotrexate (MTX) and ionizing radiation used for CNS prophylaxis in ALL.
- To identify factors contributing to neurotoxicity and guide the development of less toxic treatment strategies.
Main Methods:
- Review and categorization of reported neurotoxicities in patients treated with MTX and/or ionizing radiation for CNS leukemia prevention.
- Temporal analysis of clinical syndromes in relation to specific treatment modalities.
Main Results:
- Combination therapies involving CNS irradiation are associated with the highest rates of neurotoxicity.
- Single-modality treatments appear safer, with high-dose intravenous (iv) methotrexate potentially being the least neurotoxic option.
Conclusions:
- CNS prophylaxis regimens for ALL require careful consideration to minimize long-term neurotoxic effects.
- Future research should focus on optimizing CNS-directed therapies to balance efficacy with neurocognitive preservation in pediatric ALL survivors.